Literature DB >> 27872064

Telavancin Is Active against Experimental Aortic Valve Endocarditis Caused by Daptomycin- and Methicillin-Resistant Staphylococcus aureus Strains.

Wessam Abdelhady1, Arnold S Bayer1,2,3, Rachelle Gonzales1, Liang Li1, Yan Q Xiong4,2,3.   

Abstract

We compared the efficacy of telavancin (TLV) and daptomycin (DAP) in an experimental rabbit endocarditis model caused by two clinically derived daptomycin-resistant (DAPr) methicillin-resistant Staphylococcus aureus (MRSA) strains. TLV treatment significantly reduced MRSA densities in all target tissues and increased the percentage of these organs rendered culture negative compared to those with the untreated control or DAP-treated animals. These results demonstrate that TLV has potent in vivo efficacy against DAPr MRSA isolates in this invasive endovascular infection model.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  DAPr MRSA; MRSA; TLV; daptomycin resistance; endocarditis; infective endocarditis; telavancin

Mesh：

Substances：

Year:  2017        PMID： 27872064      PMCID： PMC5278724          DOI： 10.1128/AAC.01877-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia.

Authors:  Vance G Fowler; Anita Justice; Catrin Moore; Daniel K Benjamin; Christopher W Woods; Steven Campbell; L Barth Reller; G Ralph Corey; Nicholas P J Day; Sharon J Peacock
Journal:  Clin Infect Dis       Date:  2005-02-04       Impact factor: 9.079

2.  Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies.

Authors:  David J Farrell; Rodrigo E Mendes; Paul R Rhomberg; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

3.  Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.

Authors:  Andres G Madrigal; Li Basuino; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci.

Authors:  David J Farrell; Kevin M Krause; Bret M Benton
Journal:  Diagn Microbiol Infect Dis       Date:  2011-03       Impact factor: 2.803

5.  Mechanisms of daptomycin resistance in Staphylococcus aureus.

Authors:  Glenn W Kaatz; Tammy S Lundstrom; Susan M Seo
Journal:  Int J Antimicrob Agents       Date:  2006-09-11       Impact factor: 5.283

6.  Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  George Sakoulas; George M Eliopoulos; Jeff Alder; Claudie Thauvin Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

7.  Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.

Authors:  Yan Q Xiong; Wessam Abdel Hady; Arnold S Bayer; Liang Chen; Barry N Kreiswirth; Soo-Jin Yang
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

8.  Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.

Authors:  H F Chambers; L Basuino; B A Diep; J Steenbergen; S Zhang; P Tattevin; J Alder
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

9.  Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.

Authors:  José M Miró; Cristina García-de-la-Mària; Yolanda Armero; Elisa de-Lazzari; Dolors Soy; Asunción Moreno; Ana del Rio; Manel Almela; Carlos A Mestres; José M Gatell; María-Teresa Jiménez-de-Anta; Francesc Marco
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

Review 10.  Waves of resistance: Staphylococcus aureus in the antibiotic era.

Authors:  Henry F Chambers; Frank R Deleo
Journal:  Nat Rev Microbiol       Date:  2009-09       Impact factor: 60.633
View more
  2 in total

Review 1.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

2.  Case Commentary: Imipenem/Cilastatin and Fosfomycin for Refractory Methicillin-Resistant Staphylococcus aureus Infection: a Novel Combination Therapy.

Authors:  George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.